"We are pleased to have continued the solid sales and earnings growth during Q2 2011/12, delivering 11% organic growth for the first half of 2011/12 (excluding carmine price effect) and a 19% increase in EBIT," comments CEO Lars Frederiksen.
"All our divisions contributed positively and especially the Cultures & Enzymes Division has proved our resilient business model with strong growth despite the continued uncertainty around probiotic health claims in EU. Based on the solid performance in the first half we have narrowed our organic growth target from 7-10% to 8-10% (excluding carmine price effect).
As a result of Chr. Hansen’s strong cash generation the Board of Directors has decided to initiate a share buy-back program of up to EUR 80 million with the purpose to adjust our capital structure by distributing excess capital to the shareholders," says Lars Frederiksen.
Please see the interim report for further details.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2012/13 financial year was EUR 738 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.